Viking Therapeutics Inc Stock

Among the hottest investments these days are pharma and biotech companies that make weight loss drugs. Demand for these products surpasses supply, and analysts predict that sales growth for the new

Shares of Viking Therapeutics (NASDAQ: VKTX) were skyrocketing 32.3% as of 11:21 a.m. ET on Thursday. The big gain came after the clinical-stage biopharmaceutical company provided its second-quarter

Lineage Logistics, a real estate investment trust (REIT) focused on cold storage facilities, is preparing to go public. It's seeking to raise up to $3.9 billion -- a $19.2 billion valuation --

Fortunes have been made on biotech stocks over the last few decades. The secret to success has been to invest in an up-and-coming biotech company before it even had a product on the market. Ideally

Could 2024 be a breakout year for Viking Therapeutics (NASDAQ: VKTX)? The mid-cap biotech has generated more positive headlines than most of its peers. Excitement is through the roof. Due to crucial

Viking Therapeutics (NASDAQ: VKTX) has been one of the hottest healthcare stocks to own this year, thanks to hype and excitement relating to its promising weight loss treatment, VK2735. The

Altimmune (NASDAQ: ALT) and Viking Therapeutics (NASDAQ: VKTX) are a pair of biotechs planning to follow in the footsteps of Novo Nordisk and Eli Lilly and develop GLP-1-targeted medicines for

Few biotech companies have made more noise than Viking Therapeutics (NASDAQ: VKTX) this year, and that's saying something. The drugmaker had been a relatively small and unknown player in the

Altimmune (NASDAQ: ALT) and Viking Therapeutics (NASDAQ: VKTX) have a lot of features in common, but, at least for the moment, the performance of their stocks is not one of them. Whereas Viking's

Viking Therapeutics (NASDAQ: VKTX) is at an exciting point in its history. While it doesn't have any medicines approved for sale at the moment, it has a couple of mid-stage programs that are shaping

The S&P 500 remains near record levels as the markets have been strong this year. Finding good stocks to buy in such a hot market can be challenging. But a couple of growth stocks with lots of

A business can look to be in solid shape but still not necessarily be a great investment overall. A good example of that is Viking Therapeutics (NASDAQ: VKTX). The company has been doing a lot of

Viking Therapeutics (NASDAQ: VKTX) and Madrigal Pharmaceuticals (NASDAQ: MDGL) are highly prominent biotech companies that have a lot in common. Both focus on treating metabolic illnesses like liver

The biotech industry features many prominent companies that command plenty of attention on the market. And since the year started, few biotechs have made more noise than Viking Therapeutics (NASDAQ:

Viking Therapeutics (NASDAQ: VKTX) is an anomaly of sorts. Despite another underwhelming year for biotech stocks, the metabolic disease specialist has, so far, delivered a staggering 208% return on

Even if you're not an investor like Cathie Wood, who specializes in businesses that claim to have a shot at disrupting their industries, investing in aspiring disruptors can be a great tactic to

May has been an adventurous month for Viking (NYSE: VIK). The world's leading operator of river cruise sailings went public at $24 on May 1. On Wednesday, it delivered its first financial update as

Viking Therapeutics (NASDAQ: VKTX) stock is soaring. Two years ago, the share price hovered just above $2. Today, shares trade around $62. At Friday's prices, a paltry $100 investment in 2022 would

If you're looking at up-and-coming healthcare stocks with significant potential in the anti-obesity market, one company you've likely come across is Viking Therapeutics (NASDAQ: VKTX). Although the

The inviting market waters greeted a new cruise line operator earlier this month. Viking (NYSE: VIK) completed its initial public offering (IPO) on May 1, pricing a little more than 64 million

Things aren't so bad for investors right now. We are in a bull market even though the economy is still having some problems. However, this bull run won't last forever. There will be a slowdown

Up 260% so far this year, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity thanks to its increasingly promising therapies in development to treat obesity. But as wise investors know

Investing in clinical-stage pharmaceutical companies comes with a lot of risk, but also a lot of potential upside. When such a company delivers a successful product that passes regulatory muster --